Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Sars-cov-2 symbols : TAK save search
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
Published: 2022-01-25 (Crawled : 13:30) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.76%
H: 2.02%
C: 1.04%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.37%
H: 3.73%
C: 3.25%
ARCT 4 | $27.0 -3.33% -3.44% 270K
|
Health Technology
|
| O: 0.24%
H: 4.13%
C: 1.44%
arct-154 trial therapeutics response sars-cov-2 report pons antibody
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
Published: 2022-01-24 (Crawled : 14:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 1.18%
H: 0.34%
C: -0.69%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.19%
H: 0.1%
C: -0.63%
ARCT 4 | $27.0 -3.33% -3.44% 270K
|
Health Technology
|
| O: -2.85%
H: 3.12%
C: 2.09%
arct-154 trial therapeutics response sars-cov-2 pons antibody
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-10-12 (Crawled : 13:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.21%
H: 0.14%
C: -1.05%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.16%
H: 0.11%
C: -1.44%
ARCT 4 | $27.0 -3.33% -3.44% 270K
|
Health Technology
|
| O: 4.89%
H: 1.6%
C: -1.84%
vaccine phase 3 approval sars-cov-2
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-09-22 (Crawled : 12:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: -1.11%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.5%
H: 0.36%
C: -0.86%
ARCT 4 | $27.0 -3.33% -3.44% 270K
|
Health Technology
|
| O: 1.81%
H: 2.1%
C: -0.32%
phase 2 vaccine phase 3 approval sars-cov-2
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
Published: 2021-08-03 (Crawled : 12:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: -0.6%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.27%
H: 1.02%
C: 0.96%
ARCT 4 | $27.0 -3.33% -3.44% 270K
|
Health Technology
|
| O: 13.79%
H: 51.6%
C: 47.69%
phase 1 vaccine trial approval sars-cov-2
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-08-02 (Crawled : 14:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.36%
H: 0.75%
C: -0.18%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.02%
H: 0.21%
C: -0.12%
ARCT 4 | $27.0 -3.33% -3.44% 270K
|
Health Technology
|
| O: 6.36%
H: 9.92%
C: 5.16%
vaccine trial approval sars-cov-2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.